Marshall Wace LLP Cuts Stock Holdings in ASP Isotopes Inc. (NASDAQ:ASPI)

Marshall Wace LLP trimmed its holdings in shares of ASP Isotopes Inc. (NASDAQ:ASPI - Free Report) by 85.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 147,997 shares of the company's stock after selling 852,717 shares during the quarter. Marshall Wace LLP owned 0.21% of ASP Isotopes worth $670,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. CenterBook Partners LP bought a new stake in shares of ASP Isotopes in the 4th quarter worth approximately $6,800,000. Geode Capital Management LLC increased its holdings in shares of ASP Isotopes by 42.7% during the third quarter. Geode Capital Management LLC now owns 1,118,423 shares of the company's stock worth $3,110,000 after buying an additional 334,836 shares in the last quarter. Rovida Investment Management Ltd acquired a new stake in ASP Isotopes in the 4th quarter valued at about $990,000. JPMorgan Chase & Co. increased its position in ASP Isotopes by 854.6% in the fourth quarter. JPMorgan Chase & Co. now owns 211,893 shares of the company's stock worth $960,000 after purchasing an additional 189,697 shares during the period. Finally, Barclays PLC grew its holdings in shares of ASP Isotopes by 438.5% in the 3rd quarter. Barclays PLC now owns 72,330 shares of the company's stock valued at $201,000 after buying an additional 58,897 shares during the period. Institutional investors and hedge funds own 16.80% of the company's stock.

Insiders Place Their Bets

In related news, CEO Paul Elliot Mann sold 316,666 shares of the company's stock in a transaction on Thursday, April 17th. The stock was sold at an average price of $5.62, for a total value of $1,779,662.92. Following the sale, the chief executive officer now directly owns 7,315,454 shares of the company's stock, valued at $41,112,851.48. This represents a 4.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Robert Ainscow sold 66,668 shares of the firm's stock in a transaction dated Thursday, April 17th. The stock was sold at an average price of $5.62, for a total value of $374,674.16. Following the completion of the transaction, the chief operating officer now directly owns 1,419,992 shares in the company, valued at $7,980,355.04. The trade was a 4.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 766,667 shares of company stock valued at $4,358,502. 21.40% of the stock is currently owned by corporate insiders.

ASP Isotopes Stock Up 0.2 %

Shares of NASDAQ ASPI traded up $0.01 during midday trading on Wednesday, reaching $5.50. The company's stock had a trading volume of 655,478 shares, compared to its average volume of 2,371,393. The company has a current ratio of 7.55, a quick ratio of 7.54 and a debt-to-equity ratio of 0.80. The stock has a 50 day simple moving average of $4.87 and a 200-day simple moving average of $5.38. The stock has a market capitalization of $412.84 million, a price-to-earnings ratio of -9.02 and a beta of 3.40. ASP Isotopes Inc. has a fifty-two week low of $1.86 and a fifty-two week high of $9.33.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.